EGFR and neoplasm: Recent meta-analyses, including key head-to-head trials comparing an anti-EGFR to bevacizumab, both added to first-line chemotherapy, strengthened the predictive role of primary tumor location in driving the choice of monoclonal antibody class when treating RAS wt mCRC patients, finally confirming the indication of chemotherapy plus an anti-EGFR for left-sided patients, while bevacizumab is the recommended choice for right-sided ones, despite the treatment goal [68,69].